Data Sheet (Cat.No.T11701)

TargetMol

J22352

Chemical Properties



CAS No. : 2252395-44-9

Formula: C24H21N3O4

Molecular Weight: 415.44

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.
Targets(IC50)	Caspase
In vitro	J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance. J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner.
In vivo	J22352 is well tolerated in mice.J22352 (10?mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate.

Solubility Information

Solubility	DMSO: 125 mg/mL (300.89 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4071 mL	12.0354 mL	24.0709 mL
5 mM	0.4814 mL	2.4071 mL	4.8142 mL
10 mM	0.2407 mL	1.2035 mL	2.4071 mL
50 mM	0.0481 mL	0.2407 mL	0.4814 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Liu JR, et al. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol. 2019 May; 163:458-471.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481